NEW YORK - eTradeWire -- Manhattan BioSolutions, Inc. ("Manhattan Bio" or "MABS") today announced that a collaborative project with Dr. Iwao Ojima's laboratory at Stony Brook University has been awarded a REACH (Research Evaluation and Commercialization Hub) Feasibility Award from the Center for Biotechnology (CfB) at Stony Brook University. The award will advance their next-generation antibody-drug conjugate (ADC) platform incorporating proprietary Taxoid (TxD) payloads. This innovative technology leverages clinically validated taxane chemistry with novel modifications designed to enhance potency and overcome common resistance mechanisms in solid tumors.

The awarded project is led by Principal Investigator Dr. Iwao Ojima, Distinguished Professor and Director of the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University, and Co-Principal Investigator Dr. Boris Shor, Director of Manhattan Bio. This work builds upon their existing partnership announced last year to develop innovative taxoid-based ADC payloads for solid tumors with high unmet medical need.

More on eTradeWire News

• Meet and Greet Author Michelle L Crocker
• Meet & Greet Award Winning Author Stacy Walsh
• Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
• EU Energy Crisis: Tickeron AI Delivers 133% Annualized Return for Hedge Funds
• HandTrucksRUs.com Highlights the Importance of Window and Door Dollies for Safer Material Handling

"This REACH award represents an important step in our ongoing collaboration with Professor Ojima's laboratory," said Dr. Shor. "The CfB's support will enable us to accelerate the development of this next-generation ADC platform incorporating structurally optimized derivatives of one of the most clinically established anticancer drug classes. These novel payloads demonstrate enhanced stability and significant potency against drug-resistant solid tumors, addressing key limitations of current ADC approaches."

The REACH program, administered by the CfB at Stony Brook University, is specifically designed to bridge the critical funding gap between academic discovery and commercial development. It provides targeted funding and strategic guidance to accelerate the translation of high-potential innovations in the biomedical field.

The TxD technology enhances Manhattan Bio' ADC capabilities by adding a powerful payload class that complements the company's existing ADC arsenal and is being validated with selected well-established solid tumor targets, creating a versatile foundation for future therapeutic development, including potential dual-warhead configurations.

More on eTradeWire News

• San Diego Mental Health Clinic Expands Access to Structured Intensive Outpatient Care for Adults
• Organic Spray Tanning Continues to Rise in Popularity Among San Diego Residents
• Growth Isn't Optional—It's Essential: LaTasha Langdon Launches a Game-Changing Resource
• FÜT Performance Launches Premium Carbon Fiber Soccer Shin Guards Designed for Modern Players
• Hinfo Digital Compendium: Two Factor Authentication for Manager Accounts, Guest Usage Charts and Ne

About Manhattan BioSolutions
Manhattan BioSolutions, Inc., is a privately held biotechnology company focused on the development of precision biologic therapies for the treatment of advanced cancers. The company advances next-generation antibody-drug conjugates (ADCs) - through collaborations with leading academic institutions. Learn more at manhattanbiosolutions.com and follow Manhattan BioSolutions on LinkedIn (https://www.linkedin.com/company/manhattanbio/) or X (https://twitter.com/TheManhattanBio)